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Cardiotoxicity is one of the most significant adverse effects of the oncologic
treatment with doxorubicin, which is responsible for a substantial morbid and mortality.
The occurrence of heart failure with ventricular dysfunction may lead to severe
cardiomyopathy and ultimately to death. Studies have focused on the effects of leucine
supplementation as a strategy to minimize or revert the clinical condition of induced
proteolysis by several clinical onsets. However, the impact of leucine supplementation
in heart failure induced by doxorubicin is unknown. Therefore, the objective of this work
is to evaluate the effects of leucine supplementation on the cardiotoxicity in the heart
of rats treated with doxorubicin. Rats treated with a 7.5 mg/kg cumulative dose of
doxorubicin for 14 days presented a dilatation of the left ventricle (LV), and a reduction of
the ejection fraction (FE). The 5% supplementation of leucine in the rats’ food prevented
the malfunctioning of the LV when administered with doxorubicin. Some alterations in
the extracellular matrix remodeling were confirmed by the increase of collagen fibers in
the doxorubicin group, which did not increase when the treatment was associated with
leucine supplementation. Leucine attenuates heart failure in this experimental model with
doxorubicin. Such protection is followed by the maintenance of interstitial collagen fibers.
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INTRODUCTION
Doxorubicin is an antineoplastic agent from the group of anthracyclines, commonly used in
a wide range of neoplasms treatment (Adão et al., 2013). Cardiotoxicity is one of the most
meaningful adverse effects of oncologic treatments causing considerable morbidity and mortality
(Raschi et al., 2010). Among the effects of chemotherapeutic agents on the cardiovascular system,
cardiomyopathy, being highly frequent and serious, is the most prominent leading to heart failure
with severe ventricular dysfunction and death (Takemura and Fujiwara, 2007; Albini et al., 2010).
Evidence show that dysfunctions in the left ventricle are closely related to the use of cumulative
doses of anthracyclines (Oliveira et al., 2017). Multiple mechanisms are involved in heart failure
induced by doxorubicin. The main hypothesis for its cardiotoxicity is the increase of oxidative
stress. Repeated administration can lead to permanent lesions at both cellular and interstitial
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levels, often associated to degeneration and cardiac muscle cells
decrease, loss of contractile elements and heart failure (Octavia
et al., 2012). Other cardiotoxic mechanisms that are induced
by anthracyclines are related to compromising of important
transcription synthesis factors involved in the regulation of
cardiac-specific genes (Gianni et al., 2008). This decrease in
the protein expression coupled with the increase degradation of
myofilaments leads to a negative balance of sarcomere proteins in
cardiac cells (Jeyaseelan et al., 1997), such as interaction decrease
between actin and myosin filaments and disorganization of the
sarcomere myosin (Bottone et al., 1998).
Efforts to reduce cardiotoxicity include alterations in
the dexamethasone molecule and/or reduction of the
therapeutic dose exposure. Alternatively, myocardial uptake of
dexamethasone was reduced after the introduction of liposome
encapsulation and the simultaneous administration of the
iron chelator, dexrazoxane was employed to minimize reactive
oxygen formation (Batist, 2007; Kaiserova et al., 2007). In
addition to their potential translational benefit, these later
strategies provided mechanistic insight into doxorubicin-linked
cardiotoxicity (Sawyer et al., 2010; Adão et al., 2013).
The regulation of the metabolism, hypertrophy and cell
apoptosis in heart failure is complex, but evidence suggests that
these processes can be modulated by vital macronutrients in the
diet, including amino acids (Layman, 2003; Kim et al., 2011).
Leucine is an amino acid of branched and aliphatic chain, and
studies have focused on the effects of the supplementation of this
amino acid as a strategy to soften or/and revert the proteolysis
in different clinical situations, such as hyperthyroidism (Fidale
et al., 2016), such as rats treated with dexamethasone (Shah
et al., 2000) and others with tumors (Ventrucci et al., 2001),
which demonstrates that leucine supplementation was efficient in
softening this damage. There is evidence that leucine has a direct
anabolic effect over protein turnover in ischemic hearts, although
there is a reduction in all circulating BCAAs in humans after a
myocardial infarction. The greatest percentage leucine decrease
happens in the circulation on the first day after a myocardial
infarction before returning to a baseline level in three days
(Szpetnar et al., 2004).
Many of the underlying mechanisms of LV dysfunction
and induced by doxorubicin, are shared by other cardiac
insufficiency forms. Studies using rats show that leucine
reduced arrhythmia and heart failure in experimental myocardial
ischemia, and can serve as an alternative energetic substrate, by
providing metabolic intermediaries directly to the tricarboxylic
acid (Marazzi et al., 2008). Therefore, the objective of this
study is to evaluate the effects of leucine supplementation
on the cardiotoxicity in the heart of Wistar rats treated with
doxorubicin.
MATERIALS AND METHODS
Thirty-six Wistar male rats, 2–3 months old, and weighing 260
± 14 grams were used (Supplementary Table 1). All animals
were provided by the Animal Experimentation Biotechnology
Center of the Federal University of Uberlândia (CEBEA-UFU)
and had free access to feed and water. The monitoring boxes
and bottles of water were exchanged for sterilized material twice
a week, according to CEBEA’s protocol. The feed was changed
at the same frequency and the leftovers were discarded. All
animal handling and exchanges were done in a BS60 BioSafety
Cabinet (Tecniplast R©) airflow biosafety cabinet. The present
study was approved by the Ethics Committee on the Use of
Animals (CEUA-UFU) under the registration number 115/14, on
12/15/2014.
Leucine Supplementation
Diets were offered for an adaptation period of 14 days before
the doxorubicin treatment. During the 14 days of treatment,
and for a 14-days period after the last injection of doxorubicin,
adding up to 42 days of diet. Composition of the standard diet
(SD) included a minimum concentration of 1.54 g/100 g (1.5%)
leucine, according to the American Institute of Nutrition (AIN-
93G) (Reeves et al., 1993) and it was provided to both control
and DOXO groups. The leucine and leucine+DOXO groups
were treated with a leucine rich diet (LRD) which consisted of
SD supplemented with 5.0 g/100 g leucine (6.5% total), as used
previously by Witham et al. (2013).
Treatment with Doxorubicin
For the treatment, 10 rats of the DOXO group received,
during 2 weeks and three times a week, intraperitoneal
injections of doxorubicin hydrochloride reaching the 7.5 mg/Kg
cumulative dose, as proposed in previous study (Campos
et al., 2011). Another group of 10 animals (Leucine+DOXO
group) was associated with this dosage regimen, and they
received, 2 weeks before the doxorubicin treatment, a 5%
leucine supplementation in their food. A group of 8 animals,
(control group), with SD, and another group of 8 animals,
(Leucine group), with LRD, received a similar dose of saline
solution for the same regimen used for the animals treated with
doxorubicin.
Echocardiography Study
In vivo cardiac function was evaluated via Transthoracic
Echocardiography 14 days after the end of the doxorubicin
treatment. All animals were anesthetized using 0.1 ml/100 g
Ketamine (10%) associated with the same dose of xylazine (2%).
Anterior thorax trichotomy was performed, and the animals were
put in 45◦ lateral decubitus. ESAOTE MyLab 30 VET gold and
a 8.0 MHz transducer of 3.0 cm depth with a sectoral angle of
75◦ were used. In M mode, to the transversal right parasternal
cut in the plan of chordae tendineae, of the left ventricle
end-diastole diameter (LVEDD) and left ventricle end-systole
diameter (LVEDS) was measured, for posterior calculation of
the shortening fraction (%FS). In the same cut, the diastolic
and systolic volumes were calculated by the Teichholz et al.
(1976) method to the posterior calculus of the ejection fraction
(%LVEF).
Histopathological Analysis
Each heart was divided into four pieces (base, middle proximal,
distal middle and apex) by making three transverse cuts. These
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pieces were fixed in a 10% formalin solution for 48 h. Material
processing followed the stages of dehydration, diaphanization,
bath and embedding in paraffin. Next, the middle proximal
segment was sectioned (5 um) and then stained for collagen using
Picrosirius Red. The histological cuts stained in Sirius red were
analyzed in the optical microscope Nikon ECLIPSE TI-S R© and
photographically registered (40x objective, 10x ocular). Each cut
had a photographical register of at least 10 fields of the free wall
of the left ventricle.
After obtaining the photomicrographs, the quantification of
the total collagen area, given in percentage, was obtained with
the aid of the threshold tool of the software ImageJ1.6.0_24. This
tool allows limiting the percentage of collagen area deposited
in the extracellular matrix in relation to the total area of the
evaluated field.
Statistical Analysis
The experimental results were expressed as mean ± standard
deviation and the normality of the data was tested using
the Shapiro-Wilk test. For the normal data, the comparisons
among groups was done through analysis of variance (ANOVA),
and after that, a Tukey’s test or Newman-Keuls Multiple
Comparison Test was performed, just in case. Statistical analysis
was done with a GraphPad statistical package Prism (5.0
version). Statistical significance was established when the value
of p < 0.05.
RESULTS
General Observations
No deaths occurred in any of the groups during the experiment.
The animals treated with doxorubicin showed lessmovement and
developed periocular and nasal exudation, as well as reddened
lesions in the legs similar to drug dermatitis.
Effects of Elevated Dietary Leucine on Left
Ventricular Dysfunction Induced by
Doxorubicin in Wistar Rats
Firstly, the protector role of the leucine induced cardiotoxicity by
doxorubicin in rats was tested. In order to achieve this purpose,
2 groups of 10 rats were injected with the 10-mg/kg cumulative
doses during 2 weeks, one of the groups also received in its
diet a 5% leucine supplementation. Fourteen days past the final
treatment, DOXO group presented a higher diameter of the left
ventricle at the end of systole (LVEDS) 4.61 ± 0.1mm, and at
the end of diastole (LVEDD) 6.72 ± 0.3mm, when compared
to Control group (LVEDS) 3.39 ± 0.7mm (p = 0.0132) and
(LVEDD) 5.76 ± 0.7mm (p = 0.045). The ejection fraction of
DOXO group was (LVEF) 64.5 ± 2%, which is 17% lower than
the control group (LVEF) 78.0 ± 7% (p = 0.0153). In groups
leucine+DOXO, diameters of left ventricle were lowest (LVEDD)
5.82± 1.0mm, (LVEDS) 3.44± 0.9mm, and the ejection fraction
(LVEF) 72.8± 17% was higher than DOXO group, however they
did not show significant differences concerning both control and
DOXO groups, as shown in Figure 1.
Leucine Effect on the Remodeling of the
Extracellular Matrix Induced by the
Treatment with Doxorubicin
Changes in the extracellular matrix remodeling were confirmed
by a greater quantity of collagen fibers in the DOXO group 4.55
± 2.6 mg/mg, when compared to the control group 2.85 ± 1.3
mg/mg (p= 0.0270) and to the leucine+DOXO group 2.97± 1.5
mg/mg (p= 0.0141), according to Figure 2.
DISCUSSION
Doxorubicin is used in antineoplasic therapies, yet it can cause
left ventricular dysfunction and heart failure (Raschi et al., 2010;
Adão et al., 2013). In this experimental model, as far as we know,
the data show for the first time that leucine is capable of reducing
the effects of the cardiotoxicity of doxorubicin. Beneficial effects
were followed by themaintenance of cardiac function and cardiac
collagen fibers.
Cardiotoxicity related to doxorubicin is a multifactorial
process, sustained by energy collapse, disturbance of homeostasis
and suppression of specific sarcomere cardiac genes, apoptosis
of cardiomyocytes followed by remodeling and dilated
cardiomyopathy (Minotti et al., 2004). The anthracyclines
also induce cardiac dysfunction because of calcium metabolism
alterations, malfunction of the sarcoplasmic reticulum pump
(SERCA), of the phospholamban (PLB) and improper opening
of ryanodine receptors (RyR2) (Lim et al., 2004; Whitehead et al.,
2006).
The results of the current study are in agreement with results
of previous studies (Campos et al., 2011) that found a significant
reduction in left ventricular ejection fraction in the group of
rats treated with a cumulative dose of 15 mg/Kg of doxorubicin.
The ejection fraction was lower than the control seven days
after the last injection. And the groups treated with 3.75mg and
7 mg/kg presented a significant reduction in ejection fraction
and shortening fraction in relation to the control 14 days after
the last injection. The results showed that the cardiac toxicity
of doxorubicin was effectively attenuated by elevated dietary
leucine. Maintenance of cardiac function was observed in our
data in the leucine+doxorubicin group compared to its control,
whereas the doxorubicin group alone presented reduction of the
ejection fraction when compared to the control group.
Rats treated with different cumulative doses of doxorubicin,
administered over 8 weeks, totaling 8, 12, and 16 mg/kg had
a higher area of fibrosis in the animals’ heart when compared
to the animals in the control group (Oliveira et al., 2017). We
observed the structural preservation of the rat heart in the
leucine+doxorubicin group, maintaining the amount of collagen
fibers interstitial compared to the doxorubicin group alone.
An earlier study (Ito et al., 1990) observed in a rat cardiac
muscle cell culture model that treatment with doxorubicin
resulted in a rapid and selective decrease in the expression
of specific cardiac genes. Doxorubicin selectively decreased
mRNA levels for the sarcomeric, a-actin, troponin I and myosin
light chain genes. These changes in cardiac muscle precede
ultrastructural changes associated with myofibrillar functional
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FIGURE 1 | Leucine prevents ventricular dilation and reduces the ejection fraction produced by doxorubicin. Echocardiographic images with dilation and reduction of
LV ejection fraction induced by doxorubicin and protected leucine products in the leucine+DOXO group. *p < 0.05 in relation to the Control Group (ANOVA),
†p < 0.05 in relation to the Leucine Group (ANOVA). C, Control Group; L, Leucine Group; D, DOXO Group; DL, DOXO+Leucine Group.
FIGURE 2 | Leucine preserves cardiac structure and increase of collagen fibers produced by doxorubicin. Samples of histopathological images with increased
amount of collagen fibers in the extracellular matrix induced by doxorubicin and the protective effects of leucine in the leucine+DOXO group. *p < 0.05 in relation to
Control group (ANOVA); †p < 0.05 in relation to Leucine group (ANOVA); §p < 0.05 in relation to the leucine+doxo group (ANOVA). C, Control Group; L, Leucine
Group; D, DOXO Group; DL, DOXO+Leucine Group.
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losses, such as decreased shortening fraction and ejection
fraction, according to our findings. They also observed the effect
of different concentrations 0.2 and 0.5µM of doxorubicin in
protein synthesis in cardiac cell culture after incorporation of
leucine into the culture for 4 h. After 24 h of these treatments
protein synthesis stimulated by leucine was inhibited by 41 and
68%, respectively.
Previous studies have pointed out to cardiac protection with
leucine as a therapy strategy in different models of systolic
dysfunction, suggesting that leucine acts as a nutritional sign
to stimulate protein synthesis in cardiac muscle, increasing
the availability of the eukaryotic initiation factor (eIF4B) and
activating via p70S6K and mTOR cardiac, a fact that can
have attenuated damages observed in the doxorubicin group
(Escobar et al., 2006; Canedo et al., 2010). In an experimental
hyperthyroidism model, a significant reduction of serum
CK-MB was observed in a group of rats supplemented with
5% leucine through the food, in comparison to a group with
isolated hyperthyroidism, suggesting a cardioprotective effect of
this amino acid by proteic synthesis modulation (Fidale et al.,
2013). Nevertheless, the clinical implication of this fact are
unknown and the eventual relation with leucine mechanism
is of speculative nature. In this experimental model, leucine
attenuates left ventricular dysfunction with doxorubicin and
such protection is followed by maintenance of interstitial
collagen fibers.
Leucine may protect against cardiotoxicity by preventing
the loss of post-translational efficiency and/or developmental
autophagy. Both of the efficiency and onset of autophagy are
postulated to develop in response to doxorubicin, and are
putative contributors to the cardiotoxicity.
Study Limitations
Our study has some limitations. Doxorubicin is administered in
patients with cancer, while our study investigates experimental
cardiotoxicity in rats that did not have this disease. This study
design may have influenced our results, despite the focus of
our work being the specific identification of the effect of
leucine in heart failure and quantity of collagen fiber induced
by doxorubicin. Leucine may not adequately protect against
cardiotoxicity when doxorubicin is administered at levels that
produce cancer-related lethality, moreover, the present study did
not monitor the consumption of food and water. Another aspect
is that this study did not aim at identifying the possible pathways
of doxorubicin in which leucine may have acted and improved
the animals’ cardiac conditions. In this sense, new studies should
be conducted, in order to map protein synthesis pathways and
cellular death, aiming at identifying possible interventions of
leucine in cardiac cells.
The design of the study may have influenced our results,
although the focus of our work was the specific identification of
the leucine effect on heart failure and the amount of collagen fiber
induced by doxorubicin. Another aspect is that this study did not
aim to identify the possible pathways of action of doxorubicin
in which leucine may have acted and improved the cardiac
conditions of the animals. In this sense, new studies must be
carried out in order to map pathways of protein synthesis and
cell death, in order to identify possible leucine interventions in
cardiac cells.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphys.
2017.01042/full#supplementary-material
REFERENCES
Adão, R., Keulenaer, G., Leite-Moreira, A., and Brás-Silva, C. (2013).
Cardiotoxicity associated with cancer therapy: pathophysiological
mechanisms and prevention strategies. Rev. Port. Cardiol. 32, 395–409.
doi: 10.1016/j.repc.2012.11.002
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., and Noonan,
D. M. (2010). Cardiotoxicity of anticancer drugs: the need for cardio-
oncology and cardio-oncological prevention. J. Natl. Cancer Inst. 102, 14–25.
doi: 10.1093/jnci/djp440
Batist, G. (2007). Cardiac safety of liposomal anthracyclines. Cardiovasc. Toxicol.
7, 72–74. doi: 10.1007/s12012-007-0014-4
Bottone, A. E., Voest, E. E., and de Beer, E. L. (1998). Impairment of the
actin–myosin interaction in permeabilized cardiac trabeculae after chronic
doxorubicin treatment. Clin. Cancer Res. 4, 1031–1037.
Campos, E. C., O’Connell, J. L., Malvestio, L. M., Romano, M. M.
D., Ramos, S. G., Celes, M. R. N., et al. (2011). Calpain-mediated
dystrophin disruption may be a potential structural culprit behind chronic
doxorubicin-induced cardiomyopathy. Eur. J. Pharmacol. 670, 541–553.
doi: 10.1016/j.ejphar.2011.09.021
Canedo, C. S., Demeuler, B., Ginion, A., BAyascas, J. R., Balligand, J. L.,
Alessi, D. R., et al. (2010). Activation of the cardiac mTOR/p70S6k pathway
by leucine requires PDK1 and correlates with PRAS40 phosphorylation.
Am. J. Physiol. Endocrinol. Metab. 298, 761–769. doi: 10.1152/ajpendo.004
21.2009
Escobar, J., Frank, J. W., Suryawan, A., Nguyen, H. V., Kimball, S. R., Jefferson,
L. S., et al. (2006). Regulation of cardiac and skeletal muscle protein synthesis
by individual branched-chain amino acids in neonatal pigs. Am. J. Physiol.
Endocrinol. Metab. 290, 612–621. doi: 10.1152/ajpendo.00402.2005
Fidale, T. M., Gonçalves, A., Haddad, E., Souza, F., Fidale, B. M., Veloso, F. C., et al.
(2016). Action of leucine in heart hypertrophy induced by thyroid hormone in
rats. Biosci. J. 32, 1080–1084. doi: 10.14393/BJ-v32n4a2016-32378
Fidale, T. M., Gonçalves, A., Lopes, L. T. P., Alves, P. R., Souza, F. R., Nunes, J.
E. D., et al. (2013). Effect of leucine in cardiac hypertrophy and serum creatine
kinase in rats in experimental hyperthyroidism. Biosci. J. 29, 499–505.
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N.,
and Sawyer, D. B. (2008). Anthracycline cardiotoxicity: from bench
to bedside. J. Clin. Oncol. 26, 3777–3784. doi: 10.1200/JCO.2007.
14.9401
Ito, H., Miller, S. C., Billingham, M. E., Akimoto, H., Torti, S. V., Wade, R.,
et al. (1990). Doxorubicin selectively inhibits muscle gene expression in cardiac
muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 87, 4275–4279.
doi: 10.1073/pnas.87.11.4275
Jeyaseelan, R., Poizat, C., Wu, H. Y., and Kedes, L. (1997). Molecular mechanisms
of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske
iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes
Frontiers in Physiology | www.frontiersin.org 5 January 2018 | Volume 8 | Article 1042
Fidale et al. Leucine Protects and Cardiac Dysfunction
is associated with ATP depletion in rat cardiomyocytes. J. Biol. Chem. 272,
5828–5832. doi: 10.1074/jbc.272.9.5828
Kaiserova, H., Simunek, T., Sterba, M., denHartog, G. J., Schröterová, L., Popelová,
O., et al. (2007). New iron chelators in anthracycline-induced cardiotoxicity.
Cardiovasc. Toxicol. 7, 145–150. doi: 10.1007/s12012-007-0020-6
Kim, J. Y., Burghardt, R. C., Wu, G., Johnson, G. A., Spencer, T. E., and Bazer, F.
W. (2011). Select nutrients in the ovine uterine lumen. VII. Effects of arginine,
leucine, glutamine, and glucose on trophectoderm cell signaling, proliferation,
and migration. Biol. Reprod. 84, 62–69. doi: 10.1095/biolreprod.110.085738
Layman, D. K. (2003). The role of leucine in weight loss diets and glucose
homeostasis. J Nutr 133, 261S−267S.
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger,
H. M., et al. (2004). Anthracyclines induce calpain-dependent titin
proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 279, 8290–8299.
doi: 10.1074/jbc.M308033200
Marazzi, G., Rosanio, S., Caminiti, G., Dioguardi, F. S., and Mercuro, G.
(2008). The role of amino acids in the modulation of cardiac metabolism
during ischemia and heart failure. Curr. Pharm. Des. 14, 2592–2604.
doi: 10.2174/138161208786071227
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004).
Anthracyclines: molecular advances and pharmacologic developments
in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229.
doi: 10.1124/pr.56.2.6
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., and
Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: from molecular
mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 52, 1213–1225.
doi: 10.1016/j.yjmcc.2012.03.006
Oliveira, L. F. L., O’Connell, J. L., Carvalho, E. E. V., Pulici, E. C. C., Romano,
M. M. D., Maciel, B. C., et al. (2017). Comparison between radioisotope
ventriculography and echocardiography in the quantification of left ventricular
systolic function in rats exposed to doxorubicin. Arq. Bras. Cardiol. 108, 12–20.
doi: 10.5935/abc.20160194
Raschi, E., Vasina, V., Ursino, M. G., Boriani, G., Martoni, A., and
De Ponti, F. (2010). Anticancer drugs and cardiotoxicity: insights and
perspectives in the era of targeted therapy. Pharmacol. Ther. 125, 196–218.
doi: 10.1016/j.pharmthera.2009.10.002
Reeves, P. G., Nielsen, F. H., and Fahey, G. C. (1993). AIN-93 purified diets for
laboratory rodents: final report of the american institute of nutrition ad hoc
writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr
123, 1939–1951.
Sawyer, D. B., Peng, X., Chen, B., Pentassuglia, L., and Lim, C. C.
(2010). Mechanisms of anthracycline cardiac injury: can we identify
strategies for cardioprotection? Prog. Cardiovasc. Dis. 53, 105–113.
doi: 10.1016/j.pcad.2010.06.007
Shah, O. J., Anthony, J. C., Kimball, S. R., and Jefferson, L. S. (2000).
Glucocorticoids oppose translational control by leucine in skeletal muscle. Am.
J. Physiol. Endocrinol. Metab. 279, E1185–E1190.
Szpetnar, M., Pasternak, K., and Boguszewska, A. (2004). Branched chain amino
acids (BCAAs) in heart diseases (ischaemic heart disease and myocardial
infarction). Ann. Univ. Mariae Curie Sklodowska Med. 59, 91–95.
Takemura, G., and Fujiwara, H. (2007). Doxorubicin-induced cardiomyopathy
from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 49,
330–352. doi: 10.1016/j.pcad.2006.10.002
Teichholz, L. E., Kreulen, T., Herman, M. V., and Gorlin, R. (1976).
Problems in echocardiographic volume determinations: echocardiographic-
angiocardiographic correlations in the presence or absence of asynergy. Am.
J. Cardiol. 37, 7–11. doi: 10.1016/0002-9149(76)90491-4
Ventrucci, G., Mello, M. A., and Gomes-Marcondes, M. C. (2001). Effect
of a leucine-supplemented diet on body composition changes in pregnant
rats bearing walker 256 tumor. Bras. J. Med. Biol. Res. 34, 333–338.
doi: 10.1590/S0100-879X2001000300006
Whitehead, N. P., Yeung, E. W., and Allen, D. G. (2006). Muscle damage in
mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin. Exp.
Pharmacol. Physiol. 33, 657–662. doi: 10.1111/j.1440-1681.2006.04394.x
Witham, W. G., Yester, K. A., and McGaffin, K. R. (2013). A high leucine
diet mitigates cardiac injury and improves survival after acute myocardial
infarction.Metab. Clin. Exp. 2, 290–302. doi: 10.1016/j.metabol.2012.07.023
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Fidale, Antunes, Alex dos Santos, Rodrigues de Souza, Deconte,
Borges Rosa de Moura, Mantovani, Alves Duarte, Roever and Resende. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 6 January 2018 | Volume 8 | Article 1042
